JP2018525006A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525006A5
JP2018525006A5 JP2018509837A JP2018509837A JP2018525006A5 JP 2018525006 A5 JP2018525006 A5 JP 2018525006A5 JP 2018509837 A JP2018509837 A JP 2018509837A JP 2018509837 A JP2018509837 A JP 2018509837A JP 2018525006 A5 JP2018525006 A5 JP 2018525006A5
Authority
JP
Japan
Prior art keywords
seq
binding domain
ligand binding
sequence identity
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018509837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525006A (ja
JP6894430B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/069918 external-priority patent/WO2017032777A1/en
Publication of JP2018525006A publication Critical patent/JP2018525006A/ja
Publication of JP2018525006A5 publication Critical patent/JP2018525006A5/ja
Application granted granted Critical
Publication of JP6894430B2 publication Critical patent/JP6894430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018509837A 2015-08-24 2016-08-24 統合された制御機能を有するキメラ抗原受容体 Active JP6894430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570545 2015-08-24
DKPA201570545 2015-08-24
EP15202592 2015-12-23
EP15202592.0 2015-12-23
PCT/EP2016/069918 WO2017032777A1 (en) 2015-08-24 2016-08-24 Chimeric antigen receptors with integrated controllable functions

Publications (3)

Publication Number Publication Date
JP2018525006A JP2018525006A (ja) 2018-09-06
JP2018525006A5 true JP2018525006A5 (enExample) 2019-09-26
JP6894430B2 JP6894430B2 (ja) 2021-06-30

Family

ID=56842804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018509837A Active JP6894430B2 (ja) 2015-08-24 2016-08-24 統合された制御機能を有するキメラ抗原受容体

Country Status (12)

Country Link
US (1) US10988542B2 (enExample)
EP (1) EP3341410B1 (enExample)
JP (1) JP6894430B2 (enExample)
KR (1) KR20180042361A (enExample)
CN (1) CN107922498A (enExample)
AU (1) AU2016313082B2 (enExample)
BR (1) BR112018002189A2 (enExample)
CA (1) CA2995632C (enExample)
IL (1) IL257138A (enExample)
MX (1) MX2018001533A (enExample)
RU (1) RU2018109426A (enExample)
WO (1) WO2017032777A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
US20230071283A1 (en) * 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102708285B1 (ko) * 2017-03-13 2024-09-20 포세이다 테라퓨틱스, 인크. 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
BR102018006205A2 (pt) * 2017-03-28 2021-03-23 Cell Design Labs, Inc. Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos
EP3609915A1 (en) * 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
AU2018270515A1 (en) * 2017-05-19 2019-12-05 The Regents Of The University Of California Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
CN107312797B (zh) * 2017-07-28 2021-06-18 广州中科蓝华生物科技有限公司 一种蛋白调控系统及其制备方法和应用
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019118885A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Nkg2d daric receptors
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CA3084551A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
CA3086032A1 (en) 2017-12-20 2019-06-27 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
TW201934575A (zh) 2018-02-11 2019-09-01 大陸商江蘇恆瑞醫藥股份有限公司 一種分離的嵌合抗原受體以及包含其的修飾t細胞及用途
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019210280A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Anti-bcma car-t-cells for plasma cell depletion
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
EP4588483A3 (en) * 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
JP2022512594A (ja) * 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体(car)の群
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
CN113543797A (zh) * 2019-01-04 2021-10-22 芝加哥大学 用于调节rna的系统和方法
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
EP3966245A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd33-binding polypeptides and uses thereof
EP3966338A1 (en) * 2019-05-08 2022-03-16 Inhibrx, Inc. Cd123 targeted immunotherapies
CN114206928B (zh) * 2019-05-08 2025-08-08 印希彼生物科学公司 Cd33靶向免疫疗法
WO2020227475A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cll-1 targeted immunotherapies
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質-金属水酸化物錯体およびその方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
JP2022551820A (ja) * 2019-10-15 2022-12-14 エフ.ホフマン-ラ ロシュ アーゲー 細胞内または小胞内生体分子相互作用を検出するための人工膜貫通タンパク質
WO2021087183A1 (en) * 2019-10-31 2021-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2021116337A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021260696A1 (en) * 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
CN119638840A (zh) * 2023-09-15 2025-03-18 东莞市朋志生物科技有限公司 一种抗糖类抗原153的抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor

Similar Documents

Publication Publication Date Title
US20230025506A1 (en) Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
EP3472205B1 (en) Chimeric antigen receptor
KR102758545B1 (ko) Ctla-4 변이체 면역조절 단백질 및 이의 용도
CN112074279A (zh) 人源化bcma抗体和bcma-car-t细胞
CN118496374A (zh) 一种抗dll3嵌合抗原受体及其用途
JP2020514375A5 (enExample)
JP2020529970A5 (enExample)
CN115103852A (zh) Prame tcr受体和其用途
IL256511A (en) therapeutic factors
CA3087149A1 (en) Multi-domain immunomodulatory proteins and methods of use thereof
CN110088126A (zh) Icos配体变体免疫调节蛋白及其用途
JP2017527310A5 (enExample)
JP7723420B2 (ja) B細胞標的化並列CAR(pCAR)治療的薬剤
JP2020536552A5 (enExample)
JP2025505546A (ja) キメラilt受容体組成物及び方法
CN114555789A (zh) 工程化免疫细胞
US10882893B2 (en) TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
CN121311239A (zh) 包含替代信号传导结构域的平行嵌合抗原受体(pCAR)及衔接子嵌合抗原受体及其使用方法
US20220184130A1 (en) Artificial signalling molecule
KR20260042160A (ko) 이중특이적 폴리펩티드 분자
RU2795443C2 (ru) Гуманизированное антитело к bcma и bcma-car-nk-клетки
WO2025191154A1 (en) Therapeutic agents
NZ805407A (en) D-domain containing polypeptides and uses thereof